BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32595697)

  • 1. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Alternative mRNA Splicing Signature and a Novel Biomarker in Triple-Negative Breast Cancer.
    Liu Q; Wang X; Kong X; Yang X; Cheng R; Zhang W; Gao P; Chen L; Wang Z; Fang Y; Wang J
    DNA Cell Biol; 2020 Jun; 39(6):1051-1063. PubMed ID: 32379494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
    Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
    J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
    AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
    World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.
    Wu S; Wang J; Zhu X; Chyr J; Zhou X; Wu X; Huang L
    Front Genet; 2020; 11():604262. PubMed ID: 33519909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
    Zhang D; Duan Y; Wang Z; Lin J
    Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer.
    Lv X; He M; Zhao Y; Zhang L; Zhu W; Jiang L; Yan Y; Fan Y; Zhao H; Zhou S; Ma H; Sun Y; Li X; Xu H; Wei M
    Cancer Cell Int; 2019; 19():172. PubMed ID: 31297036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
    Zhang D; Zhang W; Sun R; Huang Z
    Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of survival-related alternative splicing signatures in acute myeloid leukemia.
    Zhang B; Yang L; Wang X; Fu D
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic alternative splicing signatures in uveal melanoma.
    Xie X; Zheng X; Xie T; Cai J; Yao Y
    Int Ophthalmol; 2021 Apr; 41(4):1347-1362. PubMed ID: 33479809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.
    Sun JR; Kong CF; Lou YN; Yu R; Qu XK; Jia LQ
    Front Genet; 2020; 11():796. PubMed ID: 32793288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
    Wang N; Gu Y; Chi J; Liu X; Xiong Y; Zhong C; Wang F; Wang X; Li L
    Front Genet; 2021; 12():721873. PubMed ID: 34408776
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.